DECEMBER 2020 Ling Cui, Pamela R. Schroeder and Paul A. Sack Inpatient and Outpatient Technologies to Assist in the Management of Insulin Dosing Simplified systems were initially developed using this construct to help adjust insulin infusions, but more complex software has since been developed to account for a variety of clinical inpatient scenarios. FDA-approved inpatient electronic glycemic management systems include Glucommander (Glytec), EndoTool …
FEBRUARY 2021 Dawn Antoline-Wang Glycemia in Early COVID-19 Hospitalization Linked to Mortality Improved glycemia within the first two or three days of hospitalization is a better predictor of outcomes in COVID-19 patients than glycemia at the time of non-intensive-care-unit (ICU) hospital admission, according to new findings. Glycemia soon after direct ICU admission was not predictive of outcomes in these patients, Dr. …
JUNE 2020 DAVE MUOIO Onduo, Medtronic, Abbott, Glytec present diabetes management study data at ADA 2020 virtual conference From virtual management programs to hybrid closed loop systems, diabetes management companies put the spotlight on improved blood glucose management and positive clinical outcomes. The American Diabetes Association’s 80th Scientific Sessions kicked off this weekend, and a handful of diabetes management device-makers …
New product will be the market’s first and only to enable optimization of ALL diabetes medications, insulin and non-insulin alike.
In spite of greater than 80 medications currently available in the U.S. to treat diabetes, less than half of the estimated 22 million people prescribed one or more are maintaining blood sugar levels within the acceptable range. The consequences not only impact health status and quality of life, they add to the growing economic burden of diabetes estimated in 2017 at $327 billion. With multiple patent allowances for its novel Therapy Advisor® software-as-a-medical-device and active engagement in the FDA 510(k) process, Glytec is poised to improve these clinical and financial outcomes by helping providers more easily and efficaciously select and dose all varieties of diabetes medications. No solution of like kind is currently available, Therapy Advisor® will be the first.
The company’s growing intellectual property portfolio attests to its leadership position in diabetes medication optimization in an era of data-driven care.
Glytec, the pioneer of digital therapeutics, has been awarded another patent allowance by the United States Patent and Trademark Office (USPTO). The latest allowance references interactions between the company’s software-as-a-medical-device platform for insulin titration and multiple connected diabetes technologies, including continuous glucose monitoring (CGM) systems, smart insulin pens and insulin pumps.
The May 30, 2019 webinar will explore the keys to augmenting traditional brick-and-mortar care with virtual care for people with diabetes.
Managing the care of people with diabetes is costly and time intensive, especially for our nation’s primary care providers who shoulder 80% of that responsibility. Virtual care programs have the potential to fill critical gaps and meet increasing demands, but can they produce real results?
The company is expanding its software-as-a-medical-device platform to support the optimization of ALL diabetes medications.
The United States Patent and Trademark Office has granted Glytec another patent allowance for systems and methods related to a product registered under the brand name, Therapy Advisor®. Currently under development, the new product will extend the company’s core competencies beyond insulin optimization to include oral, inhaled and non-insulin injectable diabetes medications.
The Dario® Blood Glucose Monitoring System will be made available to hospitals and health systems using Glytec’s virtual insulin titration service for outpatients with diabetes.
Global digital therapeutics innovator, DarioHealth Corp. (Nasdaq: DRIO), today announced a joint marketing agreement with Glytec, the market leader and pioneer of insulin titration solutions for use across the full continuum of care. The agreement allows DarioHealth’s smart glucose meter (part of the Dario Blood Glucose Monitoring System) to transmit information to Glytec’s Glucommander™ Outpatient software-as-a-medical-device.
She joins Glytec in a role that will tap her skills and experience leading operations and commercialization of emerging diabetes technologies and services.
Glytec, the pioneer of digital therapeutics and leader in insulin optimization, welcomes Paula LeClair as Executive Director and General Manager, Outpatient. In the diabetes industry, LeClair’s name is synonymous with transformation and innovation.
The newest USPTO allowances describe an integrated, connected care model for optimizing insulin therapy in the outpatient setting.
The United States Patent and Trademark Office has awarded Glytec two more patent allowances acknowledging the unique characteristics of its disruptive innovations. The allowances, which comprise a total of 52 claims, describe interactions between Glytec’s solution for insulin titration and multiple current and future-state connected diabetes technologies and health information systems, including devices, apps and other form factors for blood glucose measurement, insulin delivery and patient communication.
The iGlucose® Cell-Enabled Diabetes Care Solution from Smart Meter is now compatible with Glytec’s virtual insulin titration service.
For millions of patients with diabetes who’ve been unable to achieve their treatment goals, few programs have the potential to reduce A1C faster or more effectively than Glytec’s virtual insulin titration service. The innovative service harnesses the integration of Glytec’s Glucommander™ Outpatient software with multiple connected diabetes technologies and health information systems, including those for blood glucose measurement, insulin delivery, medical record keeping and patient communication, among others. The latest company to join Glytec’s network of connected solution partners is Smart Meter, LLC, maker of the iGlucose® Cell-Enabled Diabetes Care Solution, bringing timely, complete and accurate data to insulin titration.
Furlong joins the company during a period of extraordinary growth and will assume a key leadership role in scaling commercial operations to meet evolving customer needs.
Glytec, the pioneer of personalized digital therapeutics, is pleased to announce the appointment of Ed Furlong as Chief Operating Officer. “We are thrilled to welcome Ed Furlong to our executive team,” says Glytec’s President and CEO, Bob Leonard. “Ed’s background in helping companies expand and diversify while sustaining strong financial health is ideally suited to our strategic imperatives, especially at this crucial juncture when demand for our products and services is increasing exponentially.”
New study in which insulin dosing was guided by Glytec’s Glucommander™ Outpatient observed markedly greater reductions in A1c among patients who tested blood glucose twice a day or more.
A retrospective study being presented at the 11th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) observed that use of Glytec’s Glucommander™ Outpatient for insulin therapy management combined with blood glucose self-testing at least twice a day resulted in better patient outcomes, including a 3.0% absolute reduction in A1c and virtually no hypoglycemia (0.003%) less than 54 mg/dL.
Safety and efficacy of Glytec’s eGlycemic Management System® for diabetes therapy management, and its advantages over conventional methods, is further validated by four peer-reviewed studies.
Four new studies published in the January 2018 issue of Journal of Diabetes Science and Technology (JDST) demonstrate superior patient outcomes and organizational performance with Glytec’s eGlycemic Management System® (eGMS®) versus conventional, paper-based protocols. In all instances, which included both inpatient and outpatient settings, use of eGMS® for diabetes and insulin therapy management was observed to be safer and more effective than ‘usual care,’ with lower rates of hypoglycemia, faster resolution of diabetic ketoacidosis (DKA), expedited time to target glucose, and sustained reductions in A1c. Additionally, use of eGMS® led to substantive efficiency gains in provider workflows, fewer point-of-care tests, shorter lengths of stay, and full adoption of best practices, including 96% utilization of basal bolus insulin.
The new patent allowance addresses personalized optimization of insulin and non-insulin medications alike.
Long recognized as the market leader in enterprise software solutions for insulin management, Glytec is expanding its intellectual property protections with a new patent allowance that addresses the optimization of all diabetes medications, including oral and non-insulin injectable varieties. The patent allowance, issued by the United States Patent and Trademark Office, comprises an intricate series of 24 claims that describe personalized computer-guided selection and dosing of any prescribed diabetes therapy regimen, whether insulin only, non-insulin only or combination.
The allowed patent encompasses detailed interactions between multiple connected diabetes technologies.
Glytec, the pioneer of personalized digital therapeutics, has been awarded another U.S. patent allowance for systems and methods related to insulin management in the outpatient environment. The new patent allowance comprises 30 individual claims describing a connected care model that harnesses the integration of Glytec’s software-as-a-medical-device for insulin titration with multiple current- and future-state connected diabetes technologies and health information systems, including any and all devices, apps and other form factors for blood glucose measurement, insulin delivery and patient communication.
The integrated solution will launch in pilot programs with select U.S. providers and payers early 2018.
Glytec is pleased to announce its Glucommander™ Outpatient will be integrated with Onduo’s virtual diabetes clinic to help people with type 2 diabetes more easily manage insulin therapy and achieve their glucose targets. Onduo, a joint venture of Sanofi and Verily (an Alphabet company), is developing a virtual platform that integrates hardware, such as wirelessly-connected continuous glucose monitors, software and personalized support from healthcare experts to help people manage their type 2 diabetes. The integrated solution will launch in pilot programs with select U.S. providers and payers early 2018.
The invitation-only event is being held in New York City at the Lotte New York Palace Hotel.
Glytec President and CEO, Bob Leonard, will present an update on the company at the 29th Annual Piper Jaffray Healthcare Conference, Wednesday, November 29, 2017, 3:00 pm EST.
The growing importance of quality ratings will put pressure on hospitals to meet ADA standards for insulin therapy without added manpower.
This June, Glytec came to the American Diabetes Association (ADA) Scientific Sessions with a new story to tell. In years past, Glytec came to ADA armed with data showing that eGMS, a cloud-based glycemic management decision support system, offered a superior way for hospitals to manage insulin therapy for patients. Company officials brought a new focus to the 77th Scientific Sessions in San Diego, California, saying that it’s not enough to offer better time in range. Glytec wants to show how its results translate into what matters most to payers – and a hospital’s bottom line.
A study presented at EASD 2017 shows long-term A1C reductions through personalized insulin dose adjustments every eight weeks using Glytec’s therapy management software.
More than 50 percent of all people using insulin to manage diabetes are not at their target A1C, which is why this high-risk population is a primary focus of value-based care strategies among providers and payers alike. A retrospective study presented at the Annual Meeting of the European Association for the Study of Diabetes shows that patients whose insulin therapy is guided by Glytec’s FDA-cleared Glucommander™ software not only achieve glucose control rapidly, but with ongoing personalized dose adjustments, successfully maintain A1C reductions long term.
- Page 1 of 2